在第三阶段瘤学试验中,统计学意义的生存推导脆弱性在第三阶段瘤学试验中
Alexander D Sherry1, Yufei Liu2, Pavlos Msaouel3,4
1Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
medRxiv : the preprint server for health sciences
|January 27, 2025
概括
在III期瘤学试验中的统计学意义是脆弱的. 很少有患者结果的变化会改变试验解释,这表明目前的显著性定义对于可靠的发现是不够的.
科学领域:
- 在瘤学瘤学.
- 临床试验 临床试验
- 生物统计学 生物统计学
背景情况:
- 统计学显著性是在III期瘤学试验中确定优越性的标准.
- 这种对统计学意义的依赖正日益受到挑战.
- 这项研究调查了III期瘤学试验结果的脆弱性.
研究的目的:
- 为了估计第三阶段瘤学试验的脆弱性.
- 评估小的结果变化对试验解释的影响.
- 评估瘤学当前统计学意义定义的充分性.
主要方法:
- 利用了来自230个双臂优势III期瘤学试验的卡普兰-梅尔曲线.
- 重建了个体患者数据以估计生存推断脆弱性指数 (SIFI).
- 严重脆弱性定义为SIFI ≤1%,并通过代重新分配患者计算SIFI.
主要成果:
- 这项研究分析了230项试验,涉及184,752名患者.
- 平均8名患者 (1.4%) 的改变结果可能会改变试验解释.
- 在38%的试验 (87个试验) 中观察到严重的脆弱性 (SIFI ≤1%).
- 较低的脆弱性与随后的FDA批准有关.
- P值,而不是它的二进制解释,与脆弱性相关.
结论:
- 患者结局的轻微变化可以显著改变第三阶段瘤学试验中的统计学意义.
- 目前的统计学显著性标准可能无法保证瘤学研究中的可复制结果.
- 这些发现强调了需要更强大的方法来评估试验可靠性.
相关概念视频
Cancer Survival Analysis
324
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
324
Comparing the Survival Analysis of Two or More Groups
134
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
134
Assumptions of Survival Analysis
86
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
86
Kaplan-Meier Approach
82
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
82
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
115
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
115
Censoring Survival Data
57
Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different...
57


